PARKINSON’S DISEASE: ADVANCES IN PRECLINICAL SCREENING MODELS
AbstractAbout 1.5% of the world’s population is suffering from Parkinson’s disease, mostly above 55 years of age. It is identified by dopaminergic neuron loss in the striatum’s Substantia nigra & dopamine loss (DA). The disease of Parkinson is the second most widespread neurodegenerative disorder. It adversely affects the motor system as the disease increases the destruction of the motor system. It is also known that it also affects almost other components of the brain, but slowly. By using these animal models, we got to know the process of PD, its etiology, its pathology, molecular mechanisms, and numerous other disorders. Experimental models are carried out using theses different agents such as reserpine, 6-hydroxydopamine, haloperidol, 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine, and rotenone when used to produce particular PD characteristics. In addition, genetic models are also used to understand the processes in multicellular organisms such as drosophilia and zebrafish. Behavioral studies have been conducted mainly using these multicellular organisms.
Article Information
12
4866-4873
559
1948
English
IJPSR
S. Khan, I. Ansari *, C. Singh, F. Bamne and S. Kapadia
Department of Pharmacology, Oriental College of Pharmacy, Sanpada, Navi Mumbai, Maharashtra, India.
imtiyaz.ansari@ocp.edu.in
11 January 2020
26 March 2020
29 March 2020
10.13040/IJPSR.0975-8232.11(10).4866-73
01 October 2020
Download